UCB S.A. (UCBJY) Stock Price & Analysis
UCB S.A. (UCBJY) — price $115.22 (+1.63%), as of the Oct 2, 2026 trading session; market cap $43.9B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
UCB S.A. · UCBJY · Healthcare · Biotechnology
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $115.22 | |
| Change on the day | +1.63% | |
| 52-week range | $112.66 – $168.76 | |
| Market capitalisation | $43.9B | |
| Price / earnings (trailing) | 17.69 | |
| Shares traded on the day | 3.1K | |
| Beta (volatility vs the S&P 500) | 0.2 | |
| Dividends per share (last 12 months) | $0.85 | |
| Dividend yield (last 12 months) | 0.74% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
So definitely a strong growth at the beginning of the year, built upon the portfolio of the growth driver that we have, which allow us to move on the right-hand side of the slide when you can see, and Sandrine will comment on that, that we have upgraded our guidance for 2026 versus what we had shared with you earlier.
Jean-Christophe Tellier · Statement from
So in summary, this first half was very strong, and it gives us the confidence to upgrade our guidance for the year.
Sandrine Dufour · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for UCB (UCBJY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the UCBJY film — every key number, told as a short cinematic story
~2 min · open the film
What is UCB (UCBJY), and what does it report?
Short answer · as of
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. UCB S.A. (UCBJY) is classified as Healthcare / Biotechnology. Headquarters: Allée de la Recherche, 60, Brussels, BU, 1070, BE. It employs 10,117 people and is led by Jean-Christophe Tellier. In Q2 FY2026 it reported revenue of $4.90B and net income of $1.28B. The market values it at $43.9B.
What do the latest results show for UCB (UCBJY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $4.90B. Against analyst estimates the company has EPS beat 8 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $4.91B Jul 30, 2026
- Latest report · revenue estimate
- $4.64B Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $4.91B | $4.64B | $3.9300 | $2.9100 |
| Feb 26, 2026 | $5.02B | $4.96B | $3.7900 | $2.9100 |
| Jul 31, 2025 | $3.99B | $3.74B | $2.0200 | $1.9300 |
| Feb 27, 2025 | $3.56B | $3.20B | $1.5500 | $1.3500 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $4.90B | $1.28B | $3.29 (diluted) |
| Q4 FY2025 | $4.75B | $1.21B | $3.12 (diluted) |
| Q2 FY2025 | $3.92B | $535M | $1.38 (diluted) |
| Q4 FY2024 | $3.78B | $965M | $2.48 (diluted) |
What are the financial strengths and risks for UCB (UCBJY)?
Short answer
The distress and quality screens read Altman Z 4.74 · Piotroski F 7. Trailing ratios: ROE 19.5% · ROA 10.6% · current ratio 1.20 · earnings yield 5.6% · free-cash-flow yield 3.8%.
What should you watch next at UCB (UCBJY)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
So definitely a strong growth at the beginning of the year, built upon the portfolio of the growth driver that we have, which allow us to move on the right-hand side of the slide when you can see, and Sandrine will comment on that, that we have upgraded our guidance for 2026 versus what we had shared with you earlier.
Jean-Christophe Tellier ·
So in summary, this first half was very strong, and it gives us the confidence to upgrade our guidance for the year.
Sandrine Dufour ·
However, as I said, overall, we expect to see an improved gross margin for the full year compared to last year, which means that the mix effect -- the mix product effect more than compensate the pricing dynamics.
Sandrine Dufour ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 0.0% Prior to period end Jun 30, 2026
- Reporting holders
- 7 Period end Jun 30, 2026
- Previous quarter · holders
- 7 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Rhumbline Advisers | 9,872 |
| Gamma Investing LLC | 1,824 |
| Atlas Capital Advisors LLC | 470 |
| Pnc Financial Services Group, INC. | 271 |
| Salomon & Ludwin, LLC | 131 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about UCB (UCBJY)?
UCB Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does BIMZELX add to UCB’s immunology franchise?
BIMZELX extends UCB’s immunology reach across several inflammatory conditions already adjacent to Cimzia’s markets. Its contribution matters not only for sales growth but also for the product mix management expects to offset pricing pressure.
How do Nayzilam and UCB’s epilepsy medicines fit together?
Briviact, Vimpat and Keppra serve epilepsy management, while Nayzilam addresses seizure clusters through an emergency nasal spray. That gives UCB exposure to ongoing neurological treatment as well as acute intervention within the same franchise.
What is the UCBJY stock price today?
The last price recorded on this page for UCB S.A. (UCBJY) is $115.22, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does UCBJY pay a dividend?
Yes. UCB S.A. (UCBJY) shows a trailing 12-month dividend yield of 0.74%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (51 figures)
The 51 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Jean-Christophe Tellier (Jul 30, 2026): So definitely a strong growth at the beginning of the year, built upon the portfolio of the growth driver that we have, which allow us to move on the right-hand side of the slide when you can see, and Sandrine will comment on that, that we have upgraded our guidance for 2026 versus what we had shared with you earlier. Sandrine Dufour (Jul 30, 2026): So in summary, this first half was very strong, and it gives us the confidence to upgrade our guidance for the year. Sandrine Dufour (Jul 30, 2026): However, as I said, overall, we expect to see an improved gross margin for the full year compared to last year, which means that the mix effect -- the mix product effect more than compensate the pricing dynamics. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 41 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $115.22 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T10:35:10.289Z. | |
px.change | Change on the day | +1.63% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $43.9B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T10:35:09.422Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Feb 25, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$1.85 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 17.69 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.1K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.2 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Allée de la Recherche, 60, Brussels, BU, 1070, BE | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 10,117 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Jean-Christophe Tellier | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $4.90B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $1.28B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-30.revenue_actual | Revenue · reported — report date 2026-07-30 | $4.91B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.revenue_estimated | Revenue · estimate — report date 2026-07-30 | $4.64B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_actual | EPS · reported — report date 2026-07-30 | $3.9300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_estimated | EPS · estimate — report date 2026-07-30 | $2.9100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.revenue_actual | Revenue · reported — report date 2026-02-26 | $5.02B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.revenue_estimated | Revenue · estimate — report date 2026-02-26 | $4.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.eps_actual | EPS · reported — report date 2026-02-26 | $3.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.eps_estimated | EPS · estimate — report date 2026-02-26 | $2.9100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-31.revenue_actual | Revenue · reported — report date 2025-07-31 | $3.99B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-31.revenue_estimated | Revenue · estimate — report date 2025-07-31 | $3.74B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-31.eps_actual | EPS · reported — report date 2025-07-31 | $2.0200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-31.eps_estimated | EPS · estimate — report date 2025-07-31 | $1.9300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-27.revenue_actual | Revenue · reported — report date 2025-02-27 | $3.56B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-27.revenue_estimated | Revenue · estimate — report date 2025-02-27 | $3.20B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-27.eps_actual | EPS · reported — report date 2025-02-27 | $1.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-27.eps_estimated | EPS · estimate — report date 2025-02-27 | $1.3500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.institutions.depth.ownership_pct | Institutional ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 7 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 7 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Rhumbline Advisers — shares in provider snapshot | 9,872 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Gamma Investing LLC — shares in provider snapshot | 1,824 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Atlas Capital Advisors LLC — shares in provider snapshot | 470 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Pnc Financial Services Group, INC. — shares in provider snapshot | 271 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Salomon & Ludwin, LLC — shares in provider snapshot | 131 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $112.66 – $168.76 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 4.74 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 19.5% · ROA 10.6% · current ratio 1.20 · earnings yield 5.6% · free-cash-flow yield 3.8% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.85 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.74% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-30.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($4.91B) with the recorded estimate ($4.64B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-30.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($3.9300) with the recorded estimate ($2.9100) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-30.revenue_actual,earn.history.depth.2026-07-30.revenue_estimated,earn.history.depth.2026-07-30.revenue_actual.comparison,earn.history.depth.2026-07-30.eps_actual.comparison,earn.history.depth.2026-07-30.eps_actual,earn.history.depth.2026-07-30.eps_estimated,earn.history.depth.2026-02-26.revenue_actual,earn.history.depth.2026-02-26.revenue_estimated,earn.history.depth.2026-02-26.eps_actual,earn.history.depth.2026-02-26.eps_estimated,earn.history.depth.2025-07-31.revenue_actual,earn.history.depth.2025-07-31.revenue_estimated,earn.history.depth.2025-07-31.eps_actual,earn.history.depth.2025-07-31.eps_estimated,earn.history.depth.2025-02-27.revenue_actual,earn.history.depth.2025-02-27.revenue_estimated,earn.history.depth.2025-02-27.eps_actual,earn.history.depth.2025-02-27.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Management outlook — dated call excerpts | Captured record · 3 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-30 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
Data provided for informational purposes only.